An interventional study of rehabilitation programme based on motor control of core muscles in Multiple Sclerosis, Pelvic Floor Disorders and Incontinence, Urinary, sponsored by Universidad Europea de Madrid. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-25.
Sponsored by Universidad Europea de Madrid · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.
Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 155th largest by planned enrollment of the 202 interventional ones that give a count, is one of 18 that started in 2024, is one of 68 with no phase, reaches primary completion later than 3 of the 55 other live ones, and was the 181st registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:
Clarity Health Technologies, Inc · Sites in Spain
Ages 18–65
Sanofi · Sites in Spain, United States, Belgium and 4 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Spain, United States, Argentina and 33 more countries
Ages 18–65
Hasselt University · Sites in Spain, Belgium, Italy
Ages 18–65 · Healthy volunteers
Hoffmann-La Roche · Sites in Spain, Argentina, Brazil and 4 more countries
Ages 10–17
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 47 · Phase 3 65 · Phase 4 17
First in 2002; this study’s year is marked. 18 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 137 across the 202 interventional studies, 360 across the 28 observational. Of the 163 that completed or were terminated, 80 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
142 of 230 have an industry lead sponsor. The 10 most frequent:
Universidad Europea de Madrid is the lead sponsor of 99 studies on the registry; 23 are open to participants now.
Universidad Europea de Madrid has 3 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
13 of the studies in Multiple Sclerosis with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT07735325University of SalamancaEffects of Sensorimotor Insoles on Stability and Gait in Patients With Multiple Sclerosis. | 2026-12 |
| NCT07152145Parc de Salut MarPilot Study of tSCS for Improving Upper Limb Function in People With Multiple Sclerosis | 2026-12 |
| NCT06968676Universidad Rey Juan CarlosMixed Reality for Upper Limb Rehabilitation in People With Multiple Sclerosis (VIRTUALDOMUS) | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 230 studies in Multiple Sclerosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Given the structural relationship of the CORE as a whole, in this study we propose an intervention based on the global motor control of all the structures that make up the CORE to assess its effectiveness on urinary incontinence, sexual dysfunction and balance, as well as its relationship with respiratory function. According to our hypothesis, a global intervention could also be taken into account during conventional treatment in the future, helping to prevent genitourinary dysfunctions derived from alterations in motor control.
Main objective:
To establish the effect of core motor control training on pelvic floor functionality in patients with multiple sclerosis.
Specific objective: To assess the effect of core motor control training on urinary incontinence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention group will come to receive the treatment focused on training the motor control of the CORE. This intervention will consist of two sessions per week in which different levels of intervention will be established: 1. - First week: Sensitisation and voluntary work of the pelvic floor musculature without increasing the increase in intra-abdominal pressure. 2. - Second week: Work on respiratory motor control and activation of the pelvic floor. 3. - Third and fourth week: Motor control work with progressive increase in intra-abdominal pressure. 4. - Fifth and sixth week: Work on dynamic motor control in dual-task situations. 5. - Seventh and eighth week: Core motor control work in functional activities.
Other: rehabilitation programme based on motor control of core muscles
The control group will be evaluated before and after 8 weeks and will continue with their usual treatment.
The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.
Difference in the percentage of initial and final maximum activity of the pelvic floor muscles.
EMG
Time frame: 8 weeks
- Differences between the initial and final thickness of the oblique abdominis and transverse oblique muscles by ultrasound.
US
Time frame: 8 weeks
- Differences in the assessment of health-related quality of life before and after the intervention measured with the I-QOL questionnaire.
IQOL
Time frame: 8 weeks
- Differences in the assessment of female UI before and after intervention using the I-CIQ questionnaire
I-CIQ
Time frame: 8 weeks
- Difference in the percentage of initial and final maximum activity of the paravertebral musculature activity.
EMG
Time frame: 8 weeks
- Differences between initial and final amplitude of initial and final diaphragmatic excursion by ultrasound.
US
Time frame: 8 weeks
- Difference between initial and final FVC/- Differences between the initial and final peak expired volume (FEV1)
spirometry
Time frame: 8 weeks
differences between peak expiratory pressure (PEM) and minimum initial and end inspiratory pressure (MIP).
PIM/PEM
Time frame: 8 weeks
balance
trunk control test and Berg Balance test
Time frame: 8 weeks
Started Feb 2024 (actual). Primary completion is estimated for Jul 2024, 4 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 4 months is below that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Europea de Madrid